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Definitions of CC licenses 8

CC BY
Free to distribute and adapt the original work, even commercially, as long as the original creation and authors are credited.
CC BY-NC
Free to adapt the original work non-commercially and, although derivative works must also acknowledge the authors and be non-commercial, they do not have to be licensed on the same terms.
CC BY-NC-ND
Free to download the original work and share it as long as the authors are credited, but the work cannot be adapted or used commercially.
CC BY, Creative Commons Attribution license; NC, Non-Commercial; ND, No Derivatives. 
Research design and methods
• Journals with an impact factor of at least 15 (on May 24, 2017) were identified using Journal Selector (Sylogent, Newtown, PA, USA).
-Journals that only publish review articles were excluded. • Information about these journals' open access policies was collected from journal websites and by email contact between June 29, 2017 and July 26, 2017 (up to three attempts).
-The least restrictive open access offered by each journal was assessed and categorized using our own classification, according to:
• whether a CC BY license was offered • whether there was an embargo prior to access • the version of the article that was available (published, accepted, submitted) ( Table 1 ). -For journals that offered a CC BY license, the following were assessed:
• the article processing charge for the license • the funding requirements for obtaining a CC BY license. -Information about other licenses and access offered was tabulated. • Emails were sent to the journals between December 6, 2017 and January 2, 2018 requesting confirmation of our findings. For more information about Open Pharma, please visit www.openpharma.blog. Open Pharma is a not-for-profit project organized by Oxford PharmaGenesis, a for-profit company. 
Conclusions
